Hyperuricemia Drugs Market Report 2026

The hyperuricemia drugs market size has grown strongly in recent years. It will grow from $5.16 billion in 2025 to $5.59 billion in 2026 at a compound annual growth rate (CAGR) of 8.4%. The growth in the historic period can be attributed to limited availability of advanced hyperuricemia drugs, increasing incidence of gout and kidney stones, lack of patient awareness about uric acid management, reliance on traditional anti-inflammatory medications, growth of hospital and clinic infrastructure.

The hyperuricemia drugs market size is expected to see strong growth in the next few years. It will grow to $7.64 billion in 2030 at a compound annual growth rate (CAGR) of 8.1%. The growth in the forecast period can be attributed to development of selective uric acid reabsorption inhibitors (suri), increasing adoption of combination therapy, rising awareness about preventive care and lifestyle modifications, expansion of homecare services, growing government initiatives for metabolic disorder management. Major trends in the forecast period include rising prevalence of hyperuricemia and gout, increased adoption of xanthine oxidase inhibitors and uricosuric agents, growth in combination therapy and supportive care medications, expansion of homecare and specialty clinics for hyperuricemia management, emphasis on lifestyle modification and preventive care supplements.

The increasing incidence of hyperuricemia and gout is expected to drive the growth of the hyperuricemia drug market in the coming years. Hyperuricemia is a condition marked by elevated uric acid levels in the blood, which can result in the development of gout, a painful type of arthritis caused by the deposition of urate crystals in the joints. The occurrence of hyperuricemia and gout is affected by factors such as genetic susceptibility, dietary patterns (particularly high purine consumption), obesity, kidney function, lifestyle factors (including alcohol intake and dehydration), certain medications, and chronic diseases such as hypertension and diabetes. Hyperuricemia drugs play a crucial role in regulating uric acid levels, thereby helping to prevent the onset and progression of hyperuricemia and gout by minimizing uric acid accumulation and relieving related symptoms. For instance, in July 2024, according to data published by The Lancet, a UK-based general medical journal, gout was 3.26 times more common in males than females globally in 2020 and showed an increase with age, with an estimated 95.8 million prevalent cases projected by 2050. Therefore, the rising incidence of hyperuricemia and gout is contributing to the growth of the hyperuricemia drug market.

Key companies operating in the hyperuricemia drug market are concentrating on the development of innovative offerings, such as therapeutically equivalent generic versions, to deliver cost-effective alternatives that improve patient access to gout treatment. Therapeutic equivalent generic versions are drugs that contain the same active ingredient as branded medications, are administered in the same dosage form, and are expected to provide the same clinical effectiveness and safety profile. For example, in January 2024, Lupin, an India-based pharmaceutical company, received approval from a US health regulator for Febuxostat Tablets (40 mg and 80 mg) and Varenicline Tablets (0.5 mg and 1 mg). These generic products are intended to offer more affordable treatment options for patients requiring hyperuricemia management (Febuxostat) and smoking cessation support (Varenicline). By introducing these generics, Lupin aims to enhance access to essential medications while capturing a share of the US pharmaceutical market and supporting patients with cost-effective healthcare alternatives.

In October 2023, Amgen Inc., a US-based pharmaceutical company, acquired Horizon Therapeutics plc for $27.8 billion. Through this strategic acquisition, Amgen Inc. aims to strengthen its commitment to delivering innovative therapies to patients, particularly in the fields of autoimmune and severe inflammatory diseases. Horizon Therapeutics plc, an Ireland-based biotechnology company, provides anti-hyperuricemic drugs, including Krystexxa (pegloticase), which is also used in the treatment of chronic gout.

Major companies operating in the hyperuricemia drugs market are Pfizer Inc., Merck & Co., Bayer AG, Sanofi SA, AstraZeneca plc, Novartis AG, Boehringer Ingelheim International GmbH, Teva Pharmaceuticals, Teijin Pharma Limited, Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals Inc., Glenmark Pharmaceuticals Ltd., Kissei Pharmaceutical Co. Ltd., Fuji Yakuhin Co. Ltd.

North America was the largest region in the hyperuricemia drugs market in 2025. The regions covered in the hyperuricemia drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the hyperuricemia drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the hyperuricemia drugs market by increasing costs for imported xanthine oxidase inhibitors, uricosuric agents, and advanced combination therapy drugs. Segments like symptomatic hyperuricemia treatments and specialty drugs are most affected, particularly in regions like North America, Europe, and Asia-Pacific that rely heavily on imports. This has led to higher treatment costs and potential delays in drug availability. On the positive side, tariffs have encouraged domestic manufacturing, innovation in drug formulations, and development of cost-effective therapies.

The hyperuricemia drugs market research report is one of a series of new reports that provides hyperuricemia drugs market statistics, including hyperuricemia drugs industry global market size, regional shares, competitors with a hyperuricemia drugs market share, detailed hyperuricemia drugs market segments, market trends and opportunities, and any further data you may need to thrive in the hyperuricemia drugs industry. This hyperuricemia drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Hyperuricemia drugs are medications prescribed to reduce elevated uric acid levels in the blood. These drugs function either by decreasing the body’s production of uric acid or by enhancing its elimination through urine. They are generally administered orally, with dosage determined by factors such as the severity of hyperuricemia, patient tolerance, and underlying health conditions.

The primary types of hyperuricemia drugs include those for asymptomatic hyperuricemia, symptomatic hyperuricemia, and others. Asymptomatic hyperuricemia refers to a condition in which high uric acid levels are present in the blood without visible symptoms, and it is commonly monitored to prevent conditions such as gout or kidney stones. Hyperuricemia drugs are classified into nonsteroidal anti-inflammatory drugs, xanthine oxidase inhibitors, selective uric acid reabsorption inhibitors (SURI), uricosuric agents, and others. These drugs are used to treat various conditions, including gout, kidney stones, and others, and are utilized by different end-users such as hospitals, homecare settings, specialty clinics, and others.

The hyperuricemia drugs market consists of sales of allopurinol, febuxostat, probenecid, and rasburicase. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.